

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**Olipudase alfa for treating Niemann-Pick disease types A  
and B [3913]**

**Final appraisal determination / Final draft guidance**

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
No significant equality issues arose during consultation.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
N/A

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE’s obligations to promote equality?
N/A

5. Have the committee’s considerations of equality issues been described in the final appraisal determination, and, if so, where?
Equalities are found in 3.25 however this section merely notes that none were identified.

**Approved by Associate Director (name):** ...Richard Diaz.....

**Date:** 26 Feb 2024